FDA Backpedals on Aduhelm Approval, Now Says Only Early Alzheimer’s Patients Should Get It
The Food and Drug Administration is altering its late and controversial commendation of a newfangled drug for Alzheimer ’s disease . The means is now commend that the drug , called Aduhelm and developed by Biogen , only be given to mass in the earliest stage of the ultimately fatal neurodegenerative condition . The decision will greatly tempt policy coverage of the treatment , which is expected to cost $ 56,000 a yr ....